Name of agency: Galliard Healthcare Communications
Address: 37-41, Bedford Row, Holborn, WC1R 4JH
Telephone: 020 7663 2250
Ranking in Healthcare Top 25: 7
% growth in healthcare fee income: N/A
Ranking in Top 150: 69
Total staff 2008: 23
Who is in the hotseat?
We have more of a ‘hotsofa’ which seats Marika Freris, Rosemary Hennings and Roland Carreras.
Sum up your agency’s 2008 in three words:
Best year ever.
Three best healthcare client or campaign wins:
Client confidentiality means we are unable to share this information with you.
Significant hires in the healthcare team in 2008:
We appointed two new Client Directors and a Creative Director.
Staffing overall 2008:
We recruited high quality people across all levels of the company in 2008.
Plans and predictions for healthcare PR in 2009:
2009 will be a tough year for healthcare PR due to the consolidation of client companies and the significant number of failures of products at Phase III.
Sustaining a strong business in an environment of fewer clients and fewer drugs to launch, against the backdrop of ever tightening restrictions on commercial activities will be the key challenge for our industry in 2009.
There is also the issue of how Pharma companies will tackle the burgeoning use of ‘social media’ as a communications channel to connect with the patients and physicians they serve.
In many respects the regulations need to ‘catch up’ and Pharma companies are on the whole, taking a ‘watch and wait’ approach. I’m sure legal teams are working hard to ensure marketers and communicators are able to participate in this growing and powerful mechanism in a meaningful way in the future.
Healthcare business or brand to watch in 2009 and why:
Small physician led biotech companies will be the ones to watch, they are driving the real innovation in developing new drugs.
How were you affected by the swine flu issue in 2009?
Thankfully, we were completely unaffected.
How is the recession affecting the healthcare market, in your eyes?
The recession is not currently affecting the pharma market at this moment. The industry specific issues outlined above are of more immediate concern. The economic climate will however cause a mid-to-long term impact, due to the squeeze on public sector spending. This will clearly cascade down to the NHS and drugs spending at some point.
One thing you won’t know about the agency:
25% of our people have a Ph.D.